Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

FRAME - tumor genome-based personalized anti-cancer vaccines off-the-shelf

Descrizione del progetto

Vaccinazione antitumorale basata sulla mutazione frame-shift

L’immunoterapia mostra un potenziale impressionante per il trattamento del cancro. Questo approccio, che comporta l’attivazione generale del sistema immunitario, trarrebbe enormi benefici se combinato con una vaccinazione tumore-specifica. Ciò è ora possibile grazie a una tecnologia che consente il sequenziamento di routine dell’intero DNA tumorale entro due settimane. Frame Cancer Therapeutics ha sviluppato un nuovo tipo di vaccino antitumorale personalizzato basato su neoantigeni condivisi indotti da mutazioni frame-shift. Queste sequenze non sono normalmente espresse e sono pertanto attaccate dal sistema immunitario, consentendo vaccini specifici per diversi tipi di tumore. Il progetto finanziato dall’UE si concentra sullo sviluppo di serie specifiche di vaccini per tumori in base alle loro mutazioni shift, fornendo un approccio efficace e meno costoso rispetto alla vaccinazione con neoantigeni basati su mutazioni puntiformi.

Obiettivo

Frame Cancer Therapeutics is a Dutch start-up that develops effective vaccines against cancer, based on frameshift mutations. Driven by the ambition to provide a therapeutic effect for up to 50% of all cancers, Frame aims to alter the status quo of cancer treatment. Our balanced team consists of top researchers and successful biotech entrepreneurs with a track record including the CEO of Crucell , and founder of ProQR.

The clinical use of so-called checkpoint inhibitors, which activate the immune system, has shown great effects, particularly for treatment of advanced melanoma. Yet, a large group of cancer patients does not benefit from this treatment alone, and the next step is to combine this general activation of the immune system with tumor-specific vaccination. This has just become possible now that entire tumor DNA sequences get to be routinely read within two weeks, as part of clinical care.

The solution that Frame Cancer Therapeutics has developed is a ground-breaking strategy for anti-cancer vaccination using off-the-shelf yet personalized cancer vaccines derived from frameshift mutations. Frame Therapeutics has discovered FRAMES, a source of shared neoantigens induced by frame-shift mutations with unique therapeutic potential. These sequences are usually not expressed in the healthy body, and thus seen as foreign by the immune system. A licensed sets of FRAMES are each specific vaccines for different tumor types (such as breast, lung, kidney, colon, uterine cancer).

Most cancer vaccination strategies are based on point mutations unique for each tumor, requiring costly individualized vaccine manufacturing. Frame Therapeutics is the first company entirely focusing on the development of cancer vaccines based on FRAMES, offering off-the-shelf personalized cancer vaccines. This approach allows for economics of scale, reducing time to treatment from months to days, which is critical to patient health, and which will imprcost/benefit ratio’s.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

FRAME PHARMACEUTICALS BV
Contribution nette de l'UE
€ 50 000,00
Indirizzo
Science Park 106
1098 XG AMSTERDAM
Paesi Bassi

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00